Cis-platinum and mitomycin-C in treatment of recurrent, metastatic, or residual uterine cervical cancer post radiation.
Fifteen patients with recurrent, metastatic, or residual cervical cancer post radiotherapy were treated by combined cis-platinum 40 mg/m2 IV and mitomycin-C 30 mg/m2 IV in day 1, repeated every 4 weeks for 3-5 cycles. The maintained therapy was performed by mitomycin-C 2 mg/day orally for 7 days, every 4 weeks for 6 cycles. Six of 15 patients (40%) showed complete remission and are alive without disease after a follow-up period of 5-41 months; 3 patients (20%) with partial remission are alive with disease after a follow-up period of 8-12.5 months; 6 patients (40%) with no remission expired with a survival time of 3-6 months. Severe anemia and leukopenia (grade 3-4) were seen in 26.66 per cent. Thrombocytopenia grade 4 was seen in 13.33 per cent of cases. Nausea and vomiting occurred in almost all patients. There were no problems with hepatotoxicity, nephrotoxicity, or ototoxicity.
Senapad
S
S
Neungton
S
S
Usavajindawath
C
C
Vijatrasil
S
S
Thaithanaisawanya
V
V
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy
D008937:Mitomycins; D016685:Mitomycin; D002945:Cisplatin